Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
Status:
Recruiting
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test alternative dosing of niraparib in patients with
newly diagnosed high-grade, advanced stage ovarian cancer. The main questions it aims to
answer are:
What is the incidence of hematologic and other adverse events? What is the incidence of dose
interruption, dose reduction and discontinuation? What is the length of time of
progression-free survival at 24 months?